These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

567 related items for PubMed ID: 19010847

  • 1. Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin.
    Pastorino F, Di Paolo D, Piccardi F, Nico B, Ribatti D, Daga A, Baio G, Neumaier CE, Brignole C, Loi M, Marimpietri D, Pagnan G, Cilli M, Lepekhin EA, Garde SV, Longhi R, Corti A, Allen TM, Wu JJ, Ponzoni M.
    Clin Cancer Res; 2008 Nov 15; 14(22):7320-9. PubMed ID: 19010847
    [Abstract] [Full Text] [Related]

  • 2. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
    Garde SV, Forté AJ, Ge M, Lepekhin EA, Panchal CJ, Rabbani SA, Wu JJ.
    Anticancer Drugs; 2007 Nov 15; 18(10):1189-200. PubMed ID: 17893520
    [Abstract] [Full Text] [Related]

  • 3. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
    Pastorino F, Brignole C, Marimpietri D, Cilli M, Gambini C, Ribatti D, Longhi R, Allen TM, Corti A, Ponzoni M.
    Cancer Res; 2003 Nov 01; 63(21):7400-9. PubMed ID: 14612539
    [Abstract] [Full Text] [Related]

  • 4. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.
    Loi M, Marchiò S, Becherini P, Di Paolo D, Soster M, Curnis F, Brignole C, Pagnan G, Perri P, Caffa I, Longhi R, Nico B, Bussolino F, Gambini C, Ribatti D, Cilli M, Arap W, Pasqualini R, Allen TM, Corti A, Ponzoni M, Pastorino F.
    J Control Release; 2010 Jul 01; 145(1):66-73. PubMed ID: 20346382
    [Abstract] [Full Text] [Related]

  • 5. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery.
    Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC.
    Clin Cancer Res; 2002 Apr 01; 8(4):1172-81. PubMed ID: 11948130
    [Abstract] [Full Text] [Related]

  • 6. Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model.
    Zhou R, Mazurchuk R, Straubinger RM.
    Cancer Res; 2002 May 01; 62(9):2561-6. PubMed ID: 11980650
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release.
    Kong G, Anyarambhatla G, Petros WP, Braun RD, Colvin OM, Needham D, Dewhirst MW.
    Cancer Res; 2000 Dec 15; 60(24):6950-7. PubMed ID: 11156395
    [Abstract] [Full Text] [Related]

  • 8. [Targeting therapy of magnetic doxorubicin liposome in nude mice bearing colon cancer].
    Zhou PH, Yao LQ, Qin XY, Shen XZ, Liu YS, Lu WY, Yao M.
    Zhonghua Yi Xue Za Zhi; 2003 Dec 10; 83(23):2073-6. PubMed ID: 14703420
    [Abstract] [Full Text] [Related]

  • 9. Doxorubicin encapsulated in sterically stabilized liposomes is superior to free drug or drug-containing conventional liposomes at suppressing growth and metastases of human lung tumor xenografts.
    Sakakibara T, Chen FA, Kida H, Kunieda K, Cuenca RE, Martin FJ, Bankert RB.
    Cancer Res; 1996 Aug 15; 56(16):3743-6. PubMed ID: 8706018
    [Abstract] [Full Text] [Related]

  • 10. Novel local drug delivery system using thermoreversible gel in combination with polymeric microspheres or liposomes.
    Arai T, Benny O, Joki T, Menon LG, Machluf M, Abe T, Carroll RS, Black PM.
    Anticancer Res; 2010 Apr 15; 30(4):1057-64. PubMed ID: 20530409
    [Abstract] [Full Text] [Related]

  • 11. Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: importance of vascular permeability within tumors.
    Ogawara K, Un K, Minato K, Tanaka K, Higaki K, Kimura T.
    Int J Pharm; 2008 Jul 09; 359(1-2):234-40. PubMed ID: 18448289
    [Abstract] [Full Text] [Related]

  • 12. Enriching lipid nanovesicles with short-chain glucosylceramide improves doxorubicin delivery and efficacy in solid tumors.
    van Lummel M, van Blitterswijk WJ, Vink SR, Veldman RJ, van der Valk MA, Schipper D, Dicheva BM, Eggermont AM, ten Hagen TL, Verheij M, Koning GA.
    FASEB J; 2011 Jan 09; 25(1):280-9. PubMed ID: 20876209
    [Abstract] [Full Text] [Related]

  • 13. Intraperitoneal administration of novel doxorubicin loaded polymeric delivery systems against peritoneal carcinomatosis: experimental study in a murine model of ovarian cancer.
    Colombo PE, Boustta M, Poujol S, Jarlier M, Bressolle F, Teulon I, Ladjemi MZ, Pinguet F, Rouanet P, Vert M.
    Gynecol Oncol; 2011 Sep 09; 122(3):632-40. PubMed ID: 21665252
    [Abstract] [Full Text] [Related]

  • 14. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells.
    Ogawara K, Un K, Tanaka K, Higaki K, Kimura T.
    J Control Release; 2009 Jan 05; 133(1):4-10. PubMed ID: 18840484
    [Abstract] [Full Text] [Related]

  • 15. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
    Wong HL, Rauth AM, Bendayan R, Wu XY.
    Eur J Pharm Biopharm; 2007 Mar 05; 65(3):300-8. PubMed ID: 17156986
    [Abstract] [Full Text] [Related]

  • 16. Improved therapeutic responses for liposomal doxorubicin targeted via thrombospondin peptidomimetics versus untargeted doxorubicin.
    Rivera-Fillat MP, Reig F, Martínez EM, Grau-Oliete MR.
    J Pept Sci; 2010 Jul 05; 16(7):315-21. PubMed ID: 20552567
    [Abstract] [Full Text] [Related]

  • 17. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
    Li X, Ding L, Xu Y, Wang Y, Ping Q.
    Int J Pharm; 2009 May 21; 373(1-2):116-23. PubMed ID: 19429296
    [Abstract] [Full Text] [Related]

  • 18. A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor.
    He X, Na MH, Kim JS, Lee GY, Park JY, Hoffman AS, Nam JO, Han SE, Sim GY, Oh YK, Kim IS, Lee BH.
    Mol Pharm; 2011 Apr 04; 8(2):430-8. PubMed ID: 21222482
    [Abstract] [Full Text] [Related]

  • 19. Schedule-dependent interaction between Doxorubicin and mTHPC-mediated photodynamic therapy in murine hepatoma in vitro and in vivo.
    Kirveliene V, Grazeliene G, Dabkeviciene D, Micke I, Kirvelis D, Juodka B, Didziapetriene J.
    Cancer Chemother Pharmacol; 2006 Jan 04; 57(1):65-72. PubMed ID: 16001168
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma.
    Huang SK, Mayhew E, Gilani S, Lasic DD, Martin FJ, Papahadjopoulos D.
    Cancer Res; 1992 Dec 15; 52(24):6774-81. PubMed ID: 1458465
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.